It gets harder to figure out as he fails DR is now
Post# of 477
“Ok, let me elaborate. I didn’t mean 7-8 years for approval. I meant that from the start of the process going all the way back to the beginning, even before they started the clinical study.”
Let’s just let UHP speak for themselves:
“In 2018, we made the decision to focus our efforts and resources on accessing these Class III markets to maximize the value potential of our HemoStyp products. The Class III PMA process required a substantial investment of time and resources so we made the strategic determination to pause our sales and marketing to non-Class III markets in order to devote our full attention to the PMA process.”
Ok, so we’ve established a 2018 baseline.
Meaning approval in 2025 or 2026.
That’s pretty negative.
But also confusing that he constantly predicted 2019 approvals.